HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of U.S. Patent No. 9,545,432, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.”
The technology described in the patent involves subjecting human dermal fibroblasts in vivo to mechanical stress, low oxygen tension, and intermittent hydrostatic pressure to produce cells that comprise chondrocytes or chondrocyte-like cells. Additionally, the patent covers subjecting the fibroblasts to a scaffold and one or more growth factors suitable to differentiate the cells.
“This patent covers our core principle of differentiating dermal fibroblasts into chondrocytes for the purpose of regenerating the disc. Fibroblast cells have proven to exhibit dramatic regenerative properties, and they appear to be an optimal cell source for degenerative disc disease,” said Pete O’Heeron, Chief Executive Officer, SpinalCyte.
With this addition, SpinalCyte’s portfolio now includes 15 U.S. and foreign patents issued and directly owned by the company, along with 37 patents pending.
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. Currently, SpinalCyte holds 15 U.S. and international issued patents and has filed for an additional 37 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement.